TrialAnnals of the rheumatic diseases2020
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
152 papers cite itlatest 60 shown
this paperpooled ittrialcites it